Cancer pipelines meet regulatory uncertainty

Wednesday, June 3, 2026 | 11:00 AM - 1:00 PM ET

ASCO arrives at a moment when both the science and the policy environment are in yet another state of flux — and oncology programs are caught in the middle.

Some regulatory changes could speed approvals. Others could stall programs years into development. Add in the immigration environment, and the US cancer research landscape looks different than it did six months ago. What does this mean in the long and short run?

Join Endpoints News and oncology insiders as we break down what's coming out of Chicago and what it means for cancer R&D.

SPONSORED BY

Sponsorship opportunities are available.
Contact Meg at mestacio@endpointsnews.com to learn how you can support Endpoints at ASCO 2026.